Prothymosin alpha: A ubiquitous polypeptide with potential use in cancer diagnosis and therapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 5, 2012, Pages 599-614

  Ioannou, Kyriaki ^a   Samara, Pinelopi ^a   Livaniou, Evangelia ^b   Derhovanessian, Evelyna ^c   Tsitsilonis, Ourania E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Anticancer therapy; Prothymosin ; Thymic peptides; Thymosin 1; Tumor markers

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BETA INTERFERON; BIOLOGICAL MARKER; CISPLATIN; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; IFOSFAMIDE; INTERLEUKIN 2; PROTHYMOSIN ALPHA; SYNTHETIC PEPTIDE; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; HYPOPHYSIS TUMOR; IMMUNOMODULATION; IMMUNOSTIMULATION; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; OVERALL SURVIVAL; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECTUM CANCER; REVIEW; RHABDOMYOSARCOMA; SINGLE DRUG DOSE; STOMACH CANCER; T CELL LYMPHOMA; THYROID CANCER; TISSUE DISTRIBUTION; TUMOR DIFFERENTIATION; URINARY TRACT CANCER;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROTEIN PRECURSORS; THYMOSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84862498160     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1222-8     Document Type: Review

References (119)

1. Miller JF (1961) Immunological function of the thymus. Lancet 2:748-749
2. Good RA, Dalmasso AP, Martinez C, Archer OK, Pierce JC, Papermaster BW (1962) The role of the thymus in development of immunologic capacity in rabbits and mice. J Exp Med 116:773-796
3. Aisenberg AC, Wilkes B (1965) Partial immunological restoration of neonatally thymectomized rats with thymus-containing diffusion chambers. Nature 205:716-717
4. Berthiaume F, Aparicio CL, Eungdamrong J, Yarmush ML (1999) Age- and disease-related decline in immune function: an opportunity for "thymus-boosting" therapies. Tissue Eng 5:499-514 (Pubitemid 129673913)
5. Schulof RS (1985) Thymic peptide hormones: basic properties and clinical applications in cancer. Crit Rev Oncol Hematol 3:309-376
6. Klein JJ, Goldstein AL, White A (1965) Enhancement of in vivo incorporation of labeled precursors into DNA and total protein of mouse lymph nodes after administration of thymic extracts. Proc Natl Acad Sci USA 53:812-817
7. Goldstein AL, Slater FD, White A (1966) Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA 56:1010-1017
8. Hooper JA, McDaniel MC, Thurman GB, Cohen GH, Schulof RS, Goldstein AL (1975) Purification and properties of bovine thymosin. Ann N Y Acad Sci 249:125-144
9. Spangelo BL, Hall NR, Goldstein AL (1987) Biology and chemistry of thymosin peptides. Modulators of immunity and neuroendocrine circuits. Ann N Y Acad Sci 496:196-204
10. Wara DW, Ammann AJ (1975) Activation of T-cell rosettes in immunodeficient patients by thymosin. Ann N Y Acad Sci 249:308-315
11. Dauphinee MJ, Talal N, Goldstein AL, White A (1974) Thymosin corrects the abnormal DNA synthetic response of NZB mouse thymocytes. Proc Natl Acad Sci USA 71:2637-2641
12. Spangelo BL, Farrimond DD, Pompilius M, Bowman KL (2000) Interleukin-1β and thymic peptide regulation of pituitary and glial cell cytokine expression and cellular proliferation. Ann N Y Acad Sci 917:597-607
13. Ho AD, Ma DD, Price G, Hunstein W, Hoffbrand AV (1983) Biochemical and immunological differentiation of human thymocytes induced by thymic hormones. Immunology 50:471-476 (Pubitemid 13015911)
14. Spangelo BL, Roach JD, Hadi F, Damavandy AA, Plieskatt J, Badamchian M (2007) Thymosin fraction-5 possesses antiproliferative properties in HL-60 human promyelocytic leukemia cells: characterization of an active peptide. Ann N Y Acad Sci 1112:305-316 (Pubitemid 47598661)
15. Khaw BA, Rule AH (1973) Immunotherapy of the Dunning leukemia with thymic extracts. Br J Cancer 28:288-292
16. Petro TM, Watson RR (1982) Resistance to L1210 mouse leukemia cells in moderately protein-malnourished BALB/c mice treated in vivo with thymosin fraction V. Cancer Res 42:2139-2145 (Pubitemid 12121421)
17. Goldstein AL (2007) History of the discovery of the thymosins. Ann N Y Acad Sci 1112:1-13
18. Haritos AA, Goodall GJ, Horecker BL (1984) Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc Natl Acad Sci USA 81:1008-1011 (Pubitemid 14125638)
19. Hannappel E, Huff T (2003) The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function. Vitam Horm 66:257-296 (Pubitemid 137640819)
20. Haritos AA, Tsolas O, Horecker BL (1984) Distribution of prothymosin alpha in rat tissues. Proc Natl Acad Sci USA 81:1391-1393 (Pubitemid 14173476)
21. Eschenfeldt WH, Berger SL (1986) The human prothymosin alpha gene is polymorphic and induced upon growth stimulation: evidence using a cloned cDNA. Proc Natl Acad Sci USA 83:9403-9407
22. Szabo P, Ehleiter D, Whittington E, Weksler ME (1992) Prothymosin alpha expression occurs during G1 in proliferating B or T lymphocytes. Biochem Biophys Res Commun 185:953-959
23. Wu CL, Shiau AL, Lin CS (1997) Prothymosin alpha promotes cell proliferation in NIH3T3 cells. Life Sci 61:2091-2101
24. Sburlati AR, Manrow RE, Berger SL (1991) Prothymosin alpha antisense oligomers inhibit myeloma cell division. Proc Natl Acad Sci USA 88:253-257 (Pubitemid 21914465)
25. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, Donnelly J, Burns D, Ng SC, Rosenberg S, Wang X (2003) Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 299:223-226 (Pubitemid 36125203)
26. Karetsou Z, Kretsovali A, Murphy C, Tsolas O, Papamarcaki T (2002) Prothymosin alpha interacts with the CREB-binding protein and potentiates transcription. EMBO Rep 3:361-366 (Pubitemid 34467607)
27. Gomez-Marquez J, Rodriguez P (1998) Prothymosin alpha is a chromatin-remodelling protein in mammalian cells. Biochem J 333:1-3 (Pubitemid 28342484)
28. Eilers M, Schirm S, Bishop JM (1991) The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J 10:133-141 (Pubitemid 21905275)
29. Niture SK, Kaspar JW, Shen J, Jaiswal AK (2010) Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244:37-42
30. Pan LX, Haritos AA, Wideman J, Komiyama T, Chang M, Stein S, Salvin SB, Horecker BL (1986) Human prothymosin alpha: amino acid sequence and immunologic properties. Arch Biochem Biophys 250:197-201 (Pubitemid 16003036)
31. Baxevanis CN, Frillingos S, Seferiadis K, Reclos GJ, Arsenis P, Katsiyiannis A, Anastasopoulos E, Tsolas O, Papamichail M (1990) Enhancement of human T lymphocyte function by prothymosin alpha: increased production of interleukin-2 and expression of interleukin-2 receptors in normal human peripheral blood T lymphocytes. Immunopharmacol Immunotoxicol 12:595-617
32. Cordero OJ, Sarandeses CS, López JL, Cancio E, Regueiro BJ, Nogueira M (1991) Prothymosin alpha enhances interleukin 2 receptor expression in normal human T-lymphocytes. Int J Immunopharmacol 13:1059-1065
33. Baxevanis CN, Thanos D, Reclos GJ, Anastasopoulos E, Tsokos GC, Papamatheakis J, Papamichail M (1992) Prothymosin alpha enhances human and murine MHC class II surface antigen expression and messenger RNA accumulation. J Immunol 148:1979-1984
34. Cordero OJ, Sarandeses CS, López JL, Nogueira M (1992) Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity. Lymphokine Cytokine Res 11:277-285
35. López-Rodríguez JL, Cordero OJ, Sarandeses C, Viñuela J, Nogueira M (1994) Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha. Lymphokine Cytokine Res 13:175-182 (Pubitemid 24206709)
36. Piñeiro A, Cordero OJ, Nogueira M (2000) Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides 21:1433-1446
37. Piñeiro A, Begoña Bugia M, Pilar Arias M, Cordero OJ, Nogueira M (2001) Identification of receptors for prothymosin alpha on human lymphocytes. Biol Chem 382:1473-1482 (Pubitemid 33062233)
38. Salgado FJ, Piñeiro A, Canda-Sánchez A, Lojo J, Nogueira M (2005) Prothymosin alpha-receptor associates with lipid rafts in PHA-stimulated lymphocytes. Mol Membr Biol 22:163-176 (Pubitemid 41020333)
39. Mosoian A, Teixeira A, Burns CS, Sander LE, Gusella GL, He C, Blander JM, Klotman P, Klotman ME (2010) Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc Natl Acad Sci USA 107:10178-10183
40. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1-5
41. Mosoian A (2011) Intracellular and extracellular cytokine-like functions of prothymosin α: implications for the development of immunotherapies. Future Med Chem 3:1199-1208
42. Bustelo XR, Otero A, Gomez-Marquez J, Freire M (1991) Expression of the rat prothymosin alpha gene during T-lymphocyte proliferation and liver regeneration. J Biol Chem 266:1443-1447 (Pubitemid 21908322)
43. Alvarez CV, Zalvide JB, Cancio E, Dieguez C, Regueiro BJ, Vega FV, Dominguez F (1993) Regulation of prothymosin alpha mRNA levels in rat pituitary tumor cells. Neuroendocrinology 57:1048-1056 (Pubitemid 23260782)
44. Wu CG, Boers W, Reitsma PR, van Deventer SJ, Chamuleau RA (1997) Overexpression of prothymosin alpha, concomitant with c-myc, during rat hepatic carcinogenesis. Biochem Biophys Res Commun 232:817-821 (Pubitemid 27214082)
45. Mori M, Barnard GF, Staniunas RJ, Jessup JM, Steele GD Jr, Chen LB (1993) Prothymosin-alpha mRNA expression correlates with that of c-myc in human colon cancer. Oncogene 8:2821-2826 (Pubitemid 23279111)
46. Wu CG, Habib NA, Mitry RR, Reitsma PH, van Deventer SJ, Chamuleau RA (1997) Overexpression of hepatic prothymosin alpha, a novel marker for hepatocellular carcinoma. Br J Cancer 76:1199-1204 (Pubitemid 27448017)
47. Sasaki H, Sato Y, Kondo S, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y (2001) Expression of the prothymosin alpha mRNA correlated with that of N-myc in neuroblastoma. Cancer Lett 168:191-195 (Pubitemid 32524281)
48. Sasaki H, Nonaka M, Fujii Y, Yamakawa Y, Fukai I, Kiriyama M, Sasaki M (2001) Expression of the prothymosin-alpha gene as a prognostic factor in lung cancer. Surg Today 31:936-938 (Pubitemid 33036173)
49. Carey KA, Segal D, Klein R, Sanigorski A, Walder K, Collier GR, Cameron-Smith D (2006) Identification of novel genes expressed during rhabdomyosarcoma differentiation using cDNA microarrays. Pathol Int 56:246-255
50. Letsas KP, Vartholomatos G, Tsepi C, Tsatsoulis A, Frangou-Lazaridis M (2007) Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers? Neoplasma 54:57-62
51. Ojima E, Inoue Y, Miki C, Mori M, Kusunoki M (2007) Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy. J Gastroenterol 42:730-736 (Pubitemid 47456760)
52. Tsitsiloni OE, Stiakakis J, Koutselinis A, Gogas J, Markopoulos C, Yialouris P, Bekris S, Panoussopoulos D, Kiortsis V, Voelter W et al (1993) Expression of alpha-thymosins in human tissues in normal and abnormal growth. Proc Natl Acad Sci USA 90:9504-9507 (Pubitemid 23315813)
53. Dominguez F, Magdalena C, Cancio E, Roson E, Paredes J, Loidi L, Zalvide J, Fraga M, Forteza J, Regueiro BJ et al (1993) Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. Eur J Cancer 29A:893-897 (Pubitemid 23083625)
54. Tsitsilonis OE, Bekris E, Voutsas IF, Baxevanis CN, Markopoulos C, Papadopoulou SA, Kontzoglou K, Stoeva S, Gogas J, Voelter W, Papamichail M (1998) The prognostic value of alpha-thymosins in breast cancer. Anticancer Res 18:1501-1508 (Pubitemid 28342551)
55. Magdalena C, Dominguez F, Loidi L, Puente JL (2000) Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer. Br J Cancer 82:584-590 (Pubitemid 30085195)
56. Suzuki S, Takahashi S, Takahashi S, Takeshita K, Hikosaka A, Wakita T, Nishiyama N, Fujita T, Okamura T, Shirai T (2006) Expression of prothymosin alpha is correlated with development and progression in human prostate cancers. Prostate 66:463-469
57. Klimentzou P, Drougou A, Fehrenbacher B, Schaller M, Voelter W, Barbatis C, Paravatou-Petsotas M, Livaniou E (2008) Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody. J Histochem Cytochem 56:1023-1031
58. Tsai YS, Jou YC, Lee GF, Chen YC, Shiau AL, Tsai HT, Wu CL, Tzai TS (2009) Aberrant prothymosin-alpha expression in human bladder cancer. Urology 73:188-192
59. Jou YC, Tung CL, Tsai YS, Shen CH, Syue-Yi C, Shiau AL, Tsai HT, Wu CL, Tzai TS (2009) Prognostic relevance of prothymosinalpha expression in human upper urinary tract transitional cell carcinoma. Urology 74:951-957
60. Fraga M, García-Caballero T, Domínguez F, Pérez-Becerra E, Beiras A, Forteza J (1993) Immunohistochemical location of prothymosin alpha in regenerating human hepatocytes and hepatocellular carcinomas. Virchows Arch A Pathol Anat Histopathol 423:449-452
61. Pawlikowski M, Winczyk K (2009) Immunohistochemical detection of prothymosin alpha in pituitary adenomas-a new marker of tumor recurrence? Folia Histochem Cytobiol 47:559-562
62. Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, Choudhary AR, Dattagupta S, Sharma MC, Ralhan R, Siu KW (2011) Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer. PLoS One 6:e19213
63. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR (2007) Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141:41-50 (Pubitemid 44918077)
64. Panneerselvam C, Haritos AA, Caldarella J, Horecker BL (1987) Prothymosin alpha in human blood. Proc Natl Acad Sci USA 84:4465-4469
65. Costopoulou D, Leondiadis L, Czarnecki J, Ferderigos N, Ithakissios DS, Livaniou E, Evangelatos GP (1998) Direct ELISA method for the specific determination of prothymosin alpha in human specimens. J Immunoassay 19:295-316 (Pubitemid 28531284)
66. Kashat L, So AK, Masui O, Wang XS, Cao J, Meng X, Macmillan C, Ailles LE, Siu KW, Ralhan R, Walfish PG (2010) Secretome-based identiication and characterization of potential biomarkers in thyroid cancer. J Proteome Res 9:5757-5769
67. Tzai TS, Tsai YS, Shiau AL, Wu CL, Shieh GS, Tsai HT (2006) Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Urology 67:294-299
68. Hersh EM, Mansell PW, Reuben JM, Rios A, Newell GR, Goldstein AL, Lynch K (1983) Leukocyte subset analysis and related immunological findings in acquired immunodeficiency disease syndrome (AIDS) and malignancies. Diagn Immunol 1:168-173
69. Sasaki H, Fujii Y, Masaoka A, Yamakawa Y, Fukai I, Kiriyama M, Saito Y, Matsui H (1997) Elevated plasma thymosin-alpha1 levels in lung cancer patients. Eur J Cardiothorac Surg 12:885-891 (Pubitemid 28088225)
70. Mitani M, Kuwabara Y, Kawamura H, Sato A, Hattori K, Fujii Y (2000) Significance of plasma thymosin alpha 1 measurements in gastric cancer patients. World J Surg 24:455-458 (Pubitemid 30158713)
71. Billich A (2002) Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs 3:698-707
72. Papanastasiou M, Baxevanis CN, Papamichail M (1992) Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha. Cancer Immunol Immunother 35:145-150
73. Baxevanis CN, Gritzapis AD, Dedoussis GV, Papadopoulos NG, Tsolas O, Papamichail M (1994) Induction of lymphokine-activated killer activity in mice by prothymosin alpha. Cancer Immunol Immunother 38:281-286 (Pubitemid 24108741)
74. Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis OE, Papamichail M (1995) Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha. Cancer Immunol Immunother 40:410-418
75. Baxevanis CN, Reclos GJ, Papamichail M (1993) Prothymosin alpha restores depressed allogeneic cell-mediated lympholysis and natural-killer-cell activity in patients with cancer. Int J Cancer 53:264-268 (Pubitemid 23042877)
76. Garbin F, Eckert K, Büttner P, Garbe C, Maurer HR (1994) Prothymosin alpha augments deficient antitumor activity of monocytes from melanoma patients in vitro. Anticancer Res 14:2405-2411
77. Eckert K, Garbin F, Maurer HR, Büttner P, Garbe C, Czarnecki J (1995) Prothymosin alpha 1 modulates lymphokine-activated killer cell activity and IL-2 production by peripheral blood lymphocytes from melanoma patients in vitro. Int J Immunopharmacol 17:555-561
78. Eckert K, Grünberg E, Immenschuh P, Garbin F, Kreuser ED, Maurer HR (1997) Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1. J Cancer Res Clin Oncol 123:420-428 (Pubitemid 27356302)
79. Garbin F, Eckert K, Immenschuh P, Kreuser ED, Maurer HR (1997) Prothymosin alpha 1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients. Int J Immunopharmacol 19:323-332 (Pubitemid 28025428)
80. Eckert K, Grünberg E, Garbin F, Maurer HR (1997) Preclinical studies with prothymosin alpha1 on mononuclear cells from tumor patients. Int J Immunopharmacol 19:493-500 (Pubitemid 28261005)
81. Baxevanis CN, Spanakos G, Voutsas IF, Gritzapis AD, Tsitsilonis OE, Mamalaki A, Papamichail M (1999) Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha. Cancer Immunol Immunother 48:71-84 (Pubitemid 29287291)
82. López-Rodríguez JL, Cordero OJ, Sarandeses C, Viñuela J, Nogueira M (1994) Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha. Lymphokine Cytokine Res 13:175-182 (Pubitemid 24206709)
83. Cordero OJ, Sarandeses C, López-Rodríguez JL, Nogueira M (1995) The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha. Immunopharmacology 29:215-223
84. Voutsas IF, Baxevanis CN, Gritzapis AD, Missitzis I, Stathopoulos GP, Archodakis G, Banis C, Voelter W, Papamichail M (2000) Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas. Cancer Immunol Immunother 49:449-458
85. Skopeliti M, Kratzer U, Altenberend F, Panayotou G, Kalbacher H, Stevanovic S, Voelter W, Tsitsilonis OE (2007) Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation. Proteomics 7:1814-1824 (Pubitemid 46911001)
86. Heidecke H, Eckert K, Schulze-Forster K, Maurer HR (1997) Prothymosin alpha 1 effects in vitro on chemotaxis, cytotoxicity and oxidative response of neutrophils from melanoma, colorectal and breast tumor patients. Int J Immunopharmacol 19:413-420 (Pubitemid 28161126)
87. Wilson CL, Monteith WB, Danell AS, Burns CS (2006) Purification and characterization of the central segment of prothymosinalpha: methodology for handling highly acidic peptides. J Pept Sci 12:721-725 (Pubitemid 44697845)
88. Cordero OJ (2011) Data on the interaction between prothymosin α and TLR4 may help to the design of new antiviral compounds. J Acquir Immune Defic Syndr 56:e110-e111
89. Skopeliti M, Iconomidou VA, Derhovanessian E, Pawelec G, Voelter W, Kalbacher H, Hamodrakas SJ, Tsitsilonis OE (2009) Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner. Mol Immunol 46:784-792
90. Skopeliti M, Voutsas IF, Klimentzou P, Tsiatas ML, Beck A, Bamias A, Moraki M, Livaniou E, Neagu M, Voelter W, Tsitsilonis OE (2006) The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients. Cancer Immunol Immunother 55:1247-1257 (Pubitemid 43992051)
91. Enkemann SA, Wang RH, Trumbore MW, Berger SL (2000) Functional discontinuities in Prothymosin α caused by caspase cleavage in apoptotic cells. J Cell Physiol 182:256-268 (Pubitemid 30022679)
92. Evstafieva AG, Belov GA, Rubtsov YP, Kalkum M, Joseph B, Chichkova NV, Sukhacheva EA, Bogdanov AA, Pettersson RF, Agol VI, Vartapetian AB (2003) Apoptosis-related fragmentation, translocation, and properties of human prothymosin alpha. Exp Cell Res 284:211-223 (Pubitemid 36324529)
93. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E (1989) Synergistic effect of thymosin alpha 1 and alpha betainterferon on NK activity in tumor-bearing mice. Int J Immunopharmacol 11:443-450 (Pubitemid 19224100)
94. Garaci E, Mastino A, Pica F, Favalli C (1990) Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother 32:154-160
95. Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, Garaci E (1992) Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 50:493-499
96. Naylor PH, Quadrini K, Garaci E, Rasi G, Hadden JW (2007) Immunopharmacology of thymosin alpha1 and cytokine synergy. Ann N Y Acad Sci 1112:235-244 (Pubitemid 47598674)
97. Garaci E, Pica F, Mastino A, Palamara AT, Belardelli F, Favalli C (1993) Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha, beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J Immunother Emphasis Tumor Immunol 13:7-17 (Pubitemid 23011930)
98. Rasi G, Silecchia G, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, Tremiterra S, Garaci E (1994) Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-Xuorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 57:701-705 (Pubitemid 24201363)
99. Silecchia G, Guarino E, Sinibaldi-Vallebona P, Pierimarchi P, Restuccia A, Spaziani E, Bernard P, Tuthill C, Garaci E, Rasi G (1999) EYcacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-Xuorouracil delivery. Cancer Immunol Immunother 48:172-178 (Pubitemid 29333860)
100. Shrivastava P, Singh SM, Singh N (2005) Antitumor activation of peritoneal macrophages by thymosin alpha-1. Cancer Invest 23:316-322 (Pubitemid 41656971)
101. Schulof RS, Lloyd MJ, Cleary PA, Palaszynski SR, Mai DA, Cox JW Jr, Alabaster O, Goldstein AL (1985) A randomized trial to evaluate the immunorestorative properties of synthetic thymosinalpha 1 in patients with lung cancer. J Biol Response Mod 4:147-158 (Pubitemid 15101417)
102. Lopez M, Carpano S, Cavaliere R, Di Lauro L, Ameglio F, Vitelli G, Frasca AM, Vici P, Pignatti F, Rosselli M et al (1994) Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol 5:741-746
103. Garaci E, Lopez M, Bonsignore G, Della Giulia M, D'Aprile M, Favalli C, Rasi G, Santini S, Capomolla E, Vici P et al (1995) Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer 31A:2403-2405 (Pubitemid 26050586)
104. Salvati F, Rasi G, Portalone L, Antilli A, Garaci E (1996) Combined treatment with thymosin-alpha1 and low-dose interferonalpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Anticancer Res 16:1001-1004 (Pubitemid 26182047)
105. Rasi G, Terzoli E, Izzo F, Pierimarchi P, Ranuzzi M, Sinibaldi-Vallebona P, Tuthill C, Garaci E (2000) Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma. Melanoma Res 10:189-192 (Pubitemid 30256882)
106. Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F; Thymosin Melanoma Investigation Group (2010) Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 28:1780-1787
107. Stefanini GF, Foschi FG, Castelli E, Marsigli L, Biselli M, Mucci F, Bernardi M, Van Thiel DH, Gasbarrini G (1998) Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 45:209-215 (Pubitemid 28067555)
108. Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, Zhao YX, Wang PJ (2004) Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 26:305-307
109. Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I (2009) A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int 3:480-489
110. Wolf E, Milazzo S, Boehm K, Zwahlen M, Horneber M (2011) Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003993.pub3
111. Butler GS, Overall CM (2009) Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov 8:935-948
112. Joly AL, Wettstein G, Mignot G, Ghiringhelli F, Garrido C (2010) Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun 2:238-247
113. Aguilera R, SaYe C, Tittarelli A, González FE, Ramírez M, Reyes D, Pereda C, Hevia D, García T, Salazar L, Ferreira A, Hermoso M, Mendoza-Naranjo A, Ferrada C, Garrido P, López MN, Salazar-Onfray F (2011) Heat-shock induction of tumorderived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 17:2474-2483
114. Zhang Y, Calderwood SK (2011) Autophagy, protein aggregation and hyperthermia: a mini-review. Int J Hyperthermia 27:409-414
115. Tang D, Kang R, Zeh HJ III, Lotze MT (2010) High-mobility group box 1 and cancer. Biochim Biophys Acta 1799:131-140
116. Saenz R, Souza Cda S, Huang CT, Larsson M, Esener S, Messmer D (2010) HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen. Vaccine 28:7556-7562
117. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178-196
118. Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Kuczyk M, Rammensee HG, Stenzl A (2009) Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69:917-927
119. Institute for Immunology and Thymus Research (2011) Responsible editor Dr. Milan C. Pesic, http://www.thymustherapy.com. Accessed 2 Sept 2011